Atorvastatin in Myeloma

This study is not yet open for participant recruitment.

Verified by Bayside Health, September 2005

First Received: September 13, 2005 Last Updated: October 10, 2006 History of Changes

Sponsored by:	Bayside Health
Information provided by:	Bayside Health
ClinicalTrials.gov Identifier:	NCT00164086

Purpose

The purpose of this trial is to study the effects of a medication already widely used to treat cardiovascular disease and diabetes, in reducing the progression of myeloma.

Condition	Intervention	Phase
Myeloma	Drug: atorvastatin	Phase I

MedlinePlus related topics: Multiple Myeloma

Drug Information available for: Atorvastatin Atorvastatin calcium

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Myeloma in remission

Exclusion Criteria:

Adverse events (AEs) to statin, already on a statin, or contraindication to statin

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00164086

Contacts

Contact: Dr Jennifer Martin, MBChB, FRACP

0405 341 676

jennifer.martin@med.monash.edu.au

Locations

Australia, Victoria
Alfred Hospital
Melbourne, Victoria, Australia, 3181

Sponsors and Collaborators

Bayside Health

Investigators

Principal Investigator:

Andrew Spencer, MBChB, FRACP, PhD

The Alfred

More Information

No publications provided

Study ID Numbers:	7/04
Study First Received:	September 13, 2005
Last Updated:	October 10, 2006
ClinicalTrials.gov Identifier:	NCT00164086 History of Changes
Health Authority:	Australia: Department of Health and Ageing Therapeutic Goods Administration

Study placed in the following topic categories:

Antimetabolites
Antilipemic Agents
Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors

Atorvastatin
Neoplasms, Plasma Cell
Multiple Myeloma

Additional relevant MeSH terms:

Antimetabolites
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Antilipemic Agents
Enzyme Inhibitors

Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pharmacologic Actions
Atorvastatin

ClinicalTrials.gov processed this record on May 06, 2009